secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2023-02-01T23:59:59+00:00
Accession:  0001193125-23-021612
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics names Timothy Keutzer Chief Operating Officer effective Feb 1, 2023
--------------------------------------------------------------------------------

- Timothy Keutzer, previously Chief Development Officer, appointed COO effective February 1, 2023.
- Base salary set at $459,000; annual cash bonus target of up to 40% of base salary.
- Grant of 4-year vesting RSUs worth $500,000 on effective date.
- Severance: 9 months salary without Cause/Good Reason; on change of control, 12 months salary plus equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523021612/0001193125-23-021612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523021612/d455024d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-021612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer